CF PharmTech, Inc. (長風藥業股份有限公司) (Stock Code: 2652) has resolved to propose the adoption of its 2025 H Share Award Scheme, seeking to enhance employee and management engagement by aligning their interests with shareholders. The proposed initiative is designed to reward contributions and foster long-term development.

The H Share Award Scheme involves the use of existing shares rather than issuing new securities. While it does not require shareholder approval under Chapter 17 of the Listing Rules, the company is subject to its own governance processes. Consequently, the scheme and related authorizations must be approved by shareholders at the general meeting.

Shareholder authorization will also be sought to grant the board or an authorized party the ability to manage all matters related to the scheme. Further details, including key terms of the H Share Award Scheme, will be provided in a circular distributed to shareholders in due course.